Literature DB >> 19885385

Immunosuppressive therapy for autoimmune inner ear disease.

Maria C Buniel1, Katie Geelan-Hansen, Peter C Weber, Vincent K Tuohy.   

Abstract

Autoimmune inner ear disease (AIED) is a rare disease that is diagnosed after clinical suspicion and response to corticosteroids. AIED manifests as progressive, bilateral, although often asynchronous, sensorineural hearing loss and can be associated with vestibular symptoms. Since its description as a defined disease entity in 1979, the initial mainstay of treatment remains high-dose corticosteroids. Several animal models have been developed to assist in determining efficacy of immunosuppression in AIED, and several clinical studies have also investigated the role of both steroid and steroid-sparing treatments. Here we discuss the basic science and clinical research surrounding the history of immunosuppressive therapy in AIED.

Entities:  

Keywords:  autoimmunity; corticosteroid; hearing loss; immunomodulation; immunosuppression

Mesh:

Substances:

Year:  2009        PMID: 19885385      PMCID: PMC2747333          DOI: 10.2217/imt.09.12

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  66 in total

1.  Spontaneous remission in experimental autoimmune labyrinthitis.

Authors:  S Yamanobe; J P Harris
Journal:  Ann Otol Rhinol Laryngol       Date:  1992-12       Impact factor: 1.547

2.  Plasmapheresis in autoimmune inner ear disease: long-term follow-up.

Authors:  C M Luetje; K I Berliner
Journal:  Am J Otol       Date:  1997-09

3.  Steroid treatment improves cochlear function in the MRL.MpJ-Fas(lpr) autoimmune mouse.

Authors:  D R Trune; R J Wobig; J B Kempton; S H Hefeneider
Journal:  Hear Res       Date:  1999-11       Impact factor: 3.208

4.  Steroid treatment in young MRL.MpJ-Fas(lpr) autoimmune mice prevents cochlear dysfunction.

Authors:  D R Trune; R J Wobig; J B Kempton; S H Hefeneider
Journal:  Hear Res       Date:  1999-11       Impact factor: 3.208

5.  Strial dysfunction in the MRL-Fas mouse.

Authors:  M J Ruckenstein; M Milburn; L Hu
Journal:  Otolaryngol Head Neck Surg       Date:  1999-10       Impact factor: 3.497

6.  Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application.

Authors:  L S Parnes; A H Sun; D J Freeman
Journal:  Laryngoscope       Date:  1999-07       Impact factor: 3.325

7.  Effects of immunosuppression on the development of cochlear disease in the MRL-Fas(lpr) mouse.

Authors:  M J Ruckenstein; A Sarwar; L Hu; H Shami; T N Marion
Journal:  Laryngoscope       Date:  1999-04       Impact factor: 3.325

8.  Etanercept therapy for immune-mediated cochleovestibular disorders: a multi-center, open-label, pilot study.

Authors:  Eric L Matteson; Hyon K Choi; Dennis S Poe; Christopher Wise; Val J Lowe; Thomas J McDonald; Mahboob U Rahman
Journal:  Arthritis Rheum       Date:  2005-06-15

9.  Induction of an inner-ear-specific autoreactive T-cell line for the diagnostic evaluation of an autoimmune disease of the inner ear.

Authors:  B Gloddek; J Gloddek; W Arnold
Journal:  Ann N Y Acad Sci       Date:  1997-12-29       Impact factor: 5.691

10.  MRL/MP-lpr/lpr mouse as a model of immune-induced sensorineural hearing loss.

Authors:  C Kusakari; K Hozawa; S Koike; M Kyogoku; T Takasaka
Journal:  Ann Otol Rhinol Laryngol Suppl       Date:  1992-10
View more
  11 in total

1.  The therapeutic efficacy of human adipose tissue-derived mesenchymal stem cells on experimental autoimmune hearing loss in mice.

Authors:  Yixuan Zhou; Jingdong Yuan; Bin Zhou; Austin J Lee; Albert J Lee; Maher Ghawji; Tai June Yoo
Journal:  Immunology       Date:  2011-03-02       Impact factor: 7.397

Review 2.  Advances in nano-based inner ear delivery systems for the treatment of sensorineural hearing loss.

Authors:  Lilun Li; Tiffany Chao; Jason Brant; Bert O'Malley; Andrew Tsourkas; Daqing Li
Journal:  Adv Drug Deliv Rev       Date:  2016-01-12       Impact factor: 15.470

3.  Immunoglobulin G4-Related Disease Presented as Recurrent Otitis Media and Mixed Hearing Loss Treated With Cyclophosphamide and Rituximab: A Case Report.

Authors:  Shao San; Chia-der Lin; Sheng-Ta Tsai; Chao-Chun Lin; Po-Chang Wu
Journal:  Arch Rheumatol       Date:  2018-11-30       Impact factor: 1.472

4.  Stem cell treatment for patients with autoimmune disease by systemic infusion of culture-expanded autologous adipose tissue derived mesenchymal stem cells.

Authors:  Jeong Chan Ra; Sung Keun Kang; Il Seob Shin; Hyeong Geun Park; Sang Aun Joo; Jeong Geun Kim; Byeong-Cheol Kang; Yong Soon Lee; Ken Nakama; Min Piao; Bertram Sohl; Andras Kurtz
Journal:  J Transl Med       Date:  2011-10-21       Impact factor: 5.531

5.  Sudden Sensorioneural Hearing Loss and Autoimmune Systemic Diseases.

Authors:  Bruno Almeida Antunes Rossini; Norma de Oliveira Penido; Mario Sergio Lei Munhoz; Eduardo Amaro Bogaz; Renata Souza Curi
Journal:  Int Arch Otorhinolaryngol       Date:  2016-07-26

6.  Mobile tablet audiometry in fluctuating autoimmune ear disease.

Authors:  Scott Kohlert; Matthew Bromwich
Journal:  J Otolaryngol Head Neck Surg       Date:  2017-03-07

Review 7.  Nanocarriers for Inner Ear Disease Therapy.

Authors:  Xiaoxiang Xu; Jianwei Zheng; Yanze He; Kun Lin; Shuang Li; Ya Zhang; Peng Song; Yuye Zhou; Xiong Chen
Journal:  Front Cell Neurosci       Date:  2021-12-03       Impact factor: 5.505

8.  Bilateral Vestibular Hypofunction: Insights in Etiologies, Clinical Subtypes, and Diagnostics.

Authors:  F Lucieer; P Vonk; N Guinand; R Stokroos; H Kingma; Raymond van de Berg
Journal:  Front Neurol       Date:  2016-03-04       Impact factor: 4.003

Review 9.  Bilateral Vestibular Weakness.

Authors:  Timothy C Hain; Marcello Cherchi; Dario Andres Yacovino
Journal:  Front Neurol       Date:  2018-05-31       Impact factor: 4.003

10.  NaCl exposure results in increased expression and processing of IL-1β in Meniere's disease patients.

Authors:  Shresh Pathak; Andrea Vambutas
Journal:  Sci Rep       Date:  2022-03-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.